Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More
By Lee Jackson January 7, 2014
Celldex Therapeutics Inc. (NASDAQ: CLDX) focuses on developing therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines. Investors are interested in Celldex because of the unmet need therapies the company is developing. Celldex is working on drug indications that include therapies for glioblastoma, breast cancer, dense deposit disease and lymphoma. A recent secondary stock offering helped shore up the company coffers. The company is to update its CDX-1135 drug status, which could be a huge catalyst. The Oppenheimer price target is set at $40. The Thomson/First Call estimate is in line at $39. Celldex closed Monday at $22.33. A move to the target would be a 65% gain for shareholders
Lehman was the fourth-largest investment bank in the US, has been in the investment banking since 1850 and it was declared bankruptcy in 2008.. E.F. Hutton, Salomon Brothers and others were gone under.. Oppenheimer is nothing comparing with these investment banking companies, their motive is to make money for themselves, sometime they pump a stock so they can get out safely with minimal loss.. if you think these articles were written in the interest of small investors, then you are either crazy or stupid..